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B cell chronic lymphocytic leukemia (B-eLL) is a hematologic neoplasm 
characterised by the proliferation and accumulation of slgM+fn+ B cells 
that fail to progress to the final stages of B cell development. The 
malignant cells in B-eLL also express the pan-T cell antigen ens, 
suggesting that eLL is a malignancy of the ens+ subset of B cells. 
Additional characteristics of the malignant clone include a low 
proliferative index, enhanced in vivo survival and constitutive expression 
of the anti-apoptosis oncoprotein bcl-2. The behaviour of leukemic ens+ 
B cells in vitro contrasts their arrested in vivo state. That is, despite the 
majority of cells being arrested in the G0 phase of the cell cycle, the 
leukemic B cells are not irreversibly frozen as they can be induced to 
differentiate to Ig-secreting cells under appropriate in vitro conditions. 
Furthermore, leukemic ens+ B cells rapidly undergo death by apoptosis 
following in vitro culture. This thesis describes the requirements for in 
vitro activation of leukemic ens+ B cells, the characterisation of the 
events involved in apoptosis of these cells as well as the identification of 
various growth factors capable of modulating these events. 
Stimulation of unfractionated peripheral blood lymphocytes (PBLs) from 
three patients with B-eLL with the phorbol ester PMA and the mitogens 
PHA and PWM resulted in significant increases in cell proliferation, RNA 
synthesis and IgM secretion when compared to unstimulated cell 
populations. PMA was the most potent inducer of IgM secretion and this 
occurred irrespective of the presence of residual T cells. PMA-induced 
proliferation and RNA synthesis were also independent of T cells. 
However, in the presence of T cells, these parameters of cellular 
activation were enhanced during in vitro culture. Thus, the inductive 
ability of PMA on leukemic ens+ B cells was independent of T cells. In 
iv 
contrast, activation and differentiation of the leukemic COS+ B cells into 
!gM-secreting cells following culture with mitogens did not occur in the 
absence of T cells. Interestingly, eo-stimulation of leukemic COS+ B cells 
with PMA and anti-Ig induced cellular responses that exceeded those 
induced by either activator alone. Thus, leukemic COS+ B cells from 
patients with B-CLL can be activated in vitro and differentiate in 
response to stimulation via both T cell-dependent and T cell-independent 
mechanisms. 
Apoptotic cell death was characterised in purified leukemic COS+ B cells 
obtained from six B-CLL patients. All leukemic COS+ B cell populations 
entered an apoptotic pathway in vitro as evidenced by a reduction in cell 
size, loss of cell viability and fragmentation of DNA into multimers of 
-180 base pairs. Following 24 hours of in vitro culture 24.0±16% of 
DNA was fragmented. After 8 days, the majority of DNA was 
fragmented, and fewer than 10% of cultured cells were viable. 
Examination of bcl-2 expression in the malignant B cells by flow 
cytometry revealed a unimodal pattern of expression in >8S% of cells 
from each B-CLL patient prior to culture. During in vitro culture, bcl-2 
expression became bimodal such that the B cells displayed a bcl-2high and 
bcl-2Iow phenotype. The level of expression by the bcl-2high cells was 
similar to that observed prior to in vitro culture, indicating that bcl-2 is 
down-regulated in apoptosing cells. Interestingly, despite this down-
regulation, the overall number of cells positive for bcl-2 remained 
constant. This suggests that the enhanced survival of leukemic COS+ B 
cells in vivo is mediated by the sustained expression of bcl-2 and that 
additional mechanisms exist capable of overriding the protective effect of 
bcl-2 when bcl-2 is present at reduced levels. 
V 
Leukemic B cell apoptosis has previously been reported to be delayed or 
prevented by IL-4, IFN-y and IFN-a. These results were confirmed in 
this study where it was found that culture of leukemic CD5+ B cells with 
IL-4 or IFN-y enhanced cell viability and delayed apoptosis in 6/6 and 5/6 
populations of leukemic B cells, respectively. This function was also 
found to be shared by IL-2, IL-6, IL-13 and TNF-a as these cytokines 
enhanced cell viability and delayed apoptosis in some of the cell 
populations examined at a level similar to that observed for IL-4 and 
IFN-y. These cytokines may mediate their effect via the expression of bcl-
2 as culture in the presence of IL-2, IL-4, IL-6, IL-13, IFN-y or TNF-a 
resulted in a higher percentage of cells displaying the bcl-2high 
phenotype, compared to unstimulated cells. Taken together, these results 
suggest that autocrine and/or paracrine growth loops may play a role in 
the pathogenesis of B-CLL and that cytokines that prevent apoptosis in 
vitro may be targets for treatment of this B cell malignancy. 
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